Expression of CXCR4, a chemokine receptor that plays a key role in tumor growth and tumor cell metastasis also its role has been described in a variety of tumors, is important in the diagnosis and treatment of cancers with this type of receptor. CXCR4 is expressed in more than 30 types of cancer, such as metastatic breast, kidney, lung, brain, prostate, breast, pancreas, ovary and melanoma, etc. Also, it contributes to tumor growth, angiogenesis, metastasis and therapeutic resistance.
The Lu-177-CIXATHER theranostic radiopharmaceutical, which is produced through labeling the Pentixather peptide with Lutetium-177, intelligently detects CXCR4 receptors. So, it can be used for eradication and treatment of tumors in which this type of receptor is expressed. Using the PRRT (Peptide Receptor Radionuclide Therapy) technique, this radiopharmaceutical binds to tumor cells quite intelligently and selectively and destroys them entirely. Moreover, being a gamma emitter, it can be used for imaging purposes and following up of the treatment.